| 3LCO: reference: Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode., Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A, Bioorg Med Chem Lett. 2010 Mar 1;20(5):1543-7. Epub 2010 Jan 21. PMID: 20137931 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).